Wockhardt Ltd.

Company Snapshot

Founded: 1967
Entity Type: Public
Employees: 2,394
Region: India
Revenue: $338.0 Millions
Revenue Year: 2023
Headquarter: Maharashtra, India
Key Geographics: U.S., Europe, India, Rest of the World
Corporate Address: D-4 MIDC, Chikalthana Chhatrapati Sambhajinagar 431006, India Tel. +91-22-2653-4444 www.wockhardt.com

Company Overview

Wockhardt Ltd., a pharmaceutical and biotechnology company, offers affordable medicines to combat numerous diseases. It is India’s leading research-based global healthcare enterprise, with relevance in the fields of pharmaceuticals, biotechnology and a chain of advanced super specialty hospitals. Wockhardt’s core business is innovation. It uses science and technology to develop medicines. The company has patented modified release formulations and recombinant biotechnology products. It has a multi-disciplinary R&D program in the areas of pharmaceutical research, biotechnology and genomics research, novel drug delivery systems, new drug discovery programs and API research. The company’s pharmaceutical contract manufacturing services include the manufacturing of sterile injectables, lyophilization and other dosage forms. It has vast international expertise in the manufacture of pharmaceuticals and biopharmaceutical formulations, as well as APIs.

Financial Highlights (FY 2023)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

Wockhardt Ltd. In Reports

Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging

BCC Research Market Report for Contract Pharmaceutical Manufacturing, Research, Development and Packaging market size and growth market forecast.

Biosimilars: Global Markets

BCC Research Market Report says biosimilars market should reach $60.1 billion by 2025 from $15.7 billion in 2020 at a compound annual growth rate (CAGR) of 30.9%

Global Markets for Generic Drugs

BCC Research Market Report says global market for generic drugs should grow from $411.6 billion in 2020 to $650.3 billion by 2025, at compound annual growth rate of 9.6%.

Wockhardt Ltd. In News

回收兩款藥物 - 澳門特別行政區政府入口網站

澳門特別行政區政府入口網站 - Jul 13, 2013

Company's Business Segments

  • Pharmaceutical : The company offers formulations, biopharmaceuticals, nutrition products, vaccines, and active pharmaceutical ingredients (APIs).

Applications/End User Industries

  • Healthcare
  • Life Sciences
  • Pharmaceuticals
  • Biopharmaceuticals